-
公开(公告)号：US20190117566A1
公开(公告)日：2019-04-25
申请号：US16087035
申请日：2017-07-05
发明人： Pankaj Soni , Premchand Dalichandji Nakhat , Ganesh Vinayak Gat , Kamal S. Mehta , Dinesh Kumar , Vikas Bali
IPC分类号： A61K9/00 , A61K31/4196 , A61K9/20 , A61K9/28
摘要： The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.
-
公开(公告)号：US10888519B2
公开(公告)日：2021-01-12
申请号：US16087035
申请日：2017-07-05
发明人： Pankaj Soni , Premchand Dalichandji Nakhat , Ganesh Vinayak Gat , Kamal S. Mehta , Dinesh Kumar , Vikas Bali
IPC分类号： A61K9/00 , A61K9/20 , A61P7/00 , A61K31/4196 , A61K9/28
摘要： The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.
-
公开(公告)号：US20210161823A1
公开(公告)日：2021-06-03
申请号：US17169120
申请日：2021-02-05
发明人： Ravikumar Nithiyanandam , Ganesh Vinayak Gat , Dinesh Kumar , Kamal S. Mehta , Premchand Dalichandji Nakhat , Vivek Jain , Priyank Sharma , Baibhav Joshi
摘要： The present invention relates to high drug load pharmaceutical compositions comprising eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.
-
公开(公告)号：US10918604B2
公开(公告)日：2021-02-16
申请号：US15742004
申请日：2016-12-16
发明人： Ravikumar Nithiyanandam , Ganesh Vinayak Gat , Dinesh Kumar , Kamal S. Mehta , Premchand Dalichandji Nakhat , Vivek Jain , Priyank Sharma , Baibhav Joshi
摘要： The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
